KMID : 1130220210250010004
|
|
Annals of Geriatric Medicine and Research 2021 Volume.25 No. 1 p.4 ~ p.9
|
|
Review of COVID-19 Vaccines and Their Evidence in Older Adults
|
|
Teo Shyh Poh
|
|
Abstract
|
|
|
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a global pandemic and significant loss of life. Older people are vulnerable to SARS-CoV-2 infections and complications; thus, they are a priority group to receive COVID-19 vaccines. This review discusses considerations for COVID-19 vaccines for older adults. The general concepts of vaccine effectiveness in older adults are described, particularly immune senescence and vaccine development approaches to improve immunogenicity. The types of COVID-19 vaccine platforms are also described before reviewing the available, although limited, evidence from phase 3 COVID-19 vaccine trials relevant to older adults. The BNT162b2 vaccine by Pfizer-BioNTech and mRNA-1273 vaccine from Moderna demonstrated high efficacy and immunogenicity, which were also observed in older people. While the ChAdOx1 nCoV-19 vaccine (AZD1222) by AstraZeneca demonstrated some efficacy in older people, the vaccine dose requires clarification through further studies. Finally, the Ad26.COV2.S vaccine by Janssen Pharmaceuticals shows promise as a single-dose vaccine with a potential durability of response.
|
|
KEYWORD
|
|
COVID-19, Aged, Older adults, Vaccines
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|
|